Maxim Group reaffirmed their buy rating on shares of Palisade Bio (NASDAQ:PALI – Free Report) in a research note released on Wednesday morning, Benzinga reports. They currently have a $22.50 target price on the stock.
Palisade Bio Stock Up 6.2 %
PALI opened at $7.74 on Wednesday. The stock has a market cap of $6.58 million, a price-to-earnings ratio of -0.29 and a beta of 1.25. Palisade Bio has a 12-month low of $3.82 and a 12-month high of $36.60. The business has a 50 day moving average of $5.77 and a 200-day moving average of $7.46.
Palisade Bio (NASDAQ:PALI – Get Free Report) last announced its quarterly earnings results on Tuesday, March 26th. The company reported ($3.75) earnings per share (EPS) for the quarter. As a group, analysts expect that Palisade Bio will post -12.29 earnings per share for the current year.
Palisade Bio Company Profile
Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid to reduce the formation of postoperative adhesions, postoperative ileus, and return of bowel function in adults.
Featured Articles
- Five stocks we like better than Palisade Bio
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- MarketBeat Week in Review – 4/29 – 5/3
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- What is Short Interest? How to Use It
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Palisade Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palisade Bio and related companies with MarketBeat.com's FREE daily email newsletter.
